公司資料
PROCEPT BioRobotics 股價、新聞與催化劑
- 股票代碼:
- PRCT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
21.09 USD (-2.59%)
收盤價
最後更新: 2026年8月17日
1.52B USD
市值
股價為何變動
Following the latest company update, “PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026”, PRCT closed down 2.59% at $21.09 on Aug 17, 2026. The move occurred in the trading session associated with this conference / presentation update.
公司概覽
Urology Robotics
PROCEPT BioRobotics develops robotic systems for the surgical treatment of benign prostatic hyperplasia. Its technology is designed to standardize tissue removal while preserving outcomes across different prostate sizes and anatomies.
Aquablation Therapy
Aquablation uses a robotically controlled, heat-free waterjet to remove obstructive prostate tissue. The procedure is planned from imaging and is intended to reduce dependence on surgeon technique compared with manually executed resection.
HYDROS Platform
The HYDROS Robotic System is the company’s current AI-enabled platform for Aquablation. Its FirstAssist AI software supports personalized image-guided planning, while recurring handpiece sales create a procedure-linked revenue stream alongside capital-system placements.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。